GPB Scientific LLC announced that the NIH completed its review or its achievement of Phase I milestones and authorized Phase II funding under a $2.2M NIH STTR Award. The award by the National Cancer Institute of the National Institutes of Health supports work by GPB Scientific, in collaboration with the University of Maryland School of Medicine and Princeton University, to scale up GPB Scientific’s microfluidic cell separation technology. GPB Scientific’s innovation displaces current centrifuge-based systems for selecting cells, such as isolating a patient’s own white blood cells from red cells and platelets to manufacture ground-breaking CAR-T cancer therapies…
Read the full story.
